Vi
Non verificato

Vividion Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute
09/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Vividion Announces Publication in Science of Preclinical Data on Covalent Inhibitors of RAS-PI3K that Block Tumor Growth
1.00
13/08/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer
1.00
04/06/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
1.00
03/04/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
1.00
22/01/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Oncologia
Vividion Therapeutics Announces Promotion of Jean Bemis to Chief Operating Officer
1.00
08/01/2025
Mercato azionario
Industria
Tecnica
Scienza
Biotecnologia
Software
Salute
Farmaceutica
Oncologia
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
1.00
08/10/2024
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Vividion Therapeutics Appoints Frank Poschen to Board of Directors
1.00
23/07/2024
Multimedialità
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
Vividion Therapeutics to Expand with New Global Research and Development Center
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0